EC approves Actelion’s Ledaga for treatment of cutaneous T-cell lymphoma
As per the Actelion recent news, the pharma’s Ledaga Chlormethine Gel 160 micrograms/g has been approved by the European Commission (EC) for CTCL MF treatment.
The European Commission (EC) has granted marketing authorization to Actelion Pharmaceuticals for its innovative Ledaga Chlormethine Gel 160 micrograms/g, designed for the treatment of cutaneous T-cell lymphoma of the mycosis fungoides-type (CTCL MF). This approval marks a significant advancement in the treatment options available for this rare and often life-threatening immune system cancer. Breakthrough in […]